aDepartment of Cardiology, General Hospital of Athens ‘Laiko’, Athens, Greece

bDepartment of Hypertension, University Medical Centre Ljubljana, Medical University Ljubljana, Slovenia

cCardiovascular Center & Clinical Pharmacology, University Hospital Gent, Belgium

d3rd Department of Internal Medicine, Papageorgiou Hospital Faculty of Medicine, Aristotle University of Thessaloniki, Greece

eCharite-Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

fAP-HP, Hopital Avicenne, Centre d’Excellence Europeen en Hypertension Arterielle, Service de Medecine Interne, INSERM UMR 942 MASCOT, Paris 13-Universite Paris Nord, Bobigny, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists)

gSchool of Medicine, University of Crete, Heraklion, Greece

hDepartment of Cardiology and Kolling Institute, Royal North Shore Hospital, St Leonards

iFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia

j1st Department of Cardiology, Interventional Electrocardiology, and Hypertension, Jagiellonian University Medical College, Krakow, Poland

kUniversity of Geneva, Switzerland

lDepartment of Hypertension. Hospital de Agudos J. M. Ramos Mejía, Buenos Aires, Argentina

mDivision of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium

nHypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy

oMedical Outpatient and Hypertension Clinic, ESH Hypertension Centre of Excellence University Hospital Basel, Basel, Switzerland

pCenter for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer University Hospital

qDepartment of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic

Correspondence to Costas Thomopoulos, MD, Head of Cardiology Department, General Hospital of Athens ‘Laiko’; 17, Ag. Thoma Street, 11527 Athens, Greece. Tel: +30 2132061032; e-mail: [email protected]

Abbreviations: ABPM, ambulatory blood pressure monitoring; ACR, albumin to creatinine ratio; AIPE, Italian Association of Preeclampsia; ART, assisted reproductive technology; ASPRE, Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention; BP, blood pressure; BUMP, Blood Pressure Monitoring in High-Risk Pregnancy to Improve the Detection and Monitoring of Hypertension; CHAP, Chronic Hypertension and Pregnancy; CHIPS, Control of Hypertension in Pregnancy Study; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESH, European Society of Hypertension; FEIRI, European/International Fibromuscular Dysplasia Registry; FET, frozen–thawed embryo transfer; FIVET, Fertilization in Vitro and Embryo Transfer; FMD, fibromuscular dysplasia; FMF, Fetal Medicine Foundation; HBPM, home blood pressure monitoring; HDP, hypertensive disorders in pregnancy; HELLP, hemolysis, elevated liver enzymes, low platelets; i.v., intravenous; ICSI, Intra-Cytoplasmic Sperm Injection; ISSHP, International Society for the Study of Hypertension in Pregnancy; IUGR, intrauterine growth restriction; IUI, intrauterine insemination; IVF, in-vitro fertilization; PIERS, Preeclampsia Integrated Estimate of Risk; PLGF, placental growth factor; PPGL, pheochromocytoma/paraganglioma; sFlt-1, soluble fms-like tyrosine kinase-1; STRIDE-BP, Science and Technology for Regional Innovation and Development in Europe – Blood Pressure

Received 25 March, 2024

Accepted 25 March, 2024

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).